Our deep knowledge and experience of healthcare, plus our extensive network and thorough processes will enable you to see your way forward. And we don’t just recommend, we do.
Are you planning on commercializing a product in Canada? More and more companies are establishing a Canadian presence. Pangaea has developed a detailed Critical Path that starts with pricing and reimbursement plans and outlines every step in the process, including timing and costs, to successfully launch in Canada.
We thought we had a view of the introduction of biosimilars in Canada which was similar to Europe. It turns out that brand is an active player and private and public payers are trying to treat them as interchangeable. Pangaea can help you stay on top of recent developments and the implications.
Recent legislation from the Minister’s office has led to an incredible amount of confusion. Regulations are now being rolled out that are answering many of the questions. Pangaea is keeping abreast of the changes and the implications. To learn about the facts, speculation and contingency advice, contact us.
Pangaea’s knowledge of the Pharmaceutical industry and understanding of where it fits in the Canadian healthcare system is unrivalled, as are its industry contacts and extensive network. What results is Pangaea’s unique strategic perspective, forward thinking and passion for the business of expanded and appropriate use of pharmaceuticals in Canada. All of that is put to work for the benefit of Pangaea clients.
—Ronnie Miller, President & CEO, Hoffmann-La Roche Limited
© 2017 Pangaea Holdings Inc. / Pangaea Group